$EDSA News

Edesa Biotech, Inc. (EDSA) Presents at Dermatology Drug Development Summit 2026 - Slideshow

Edesa Biotech, Inc. (EDSA) Presents at Respiratory Innovation Summit 2026 - Slideshow

Edesa Biotech Q2 EPS $(0.49) Misses $(0.26) Estimate

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

Edesa Biotech Reaffirms Enrollment Timeline Guidance For Phase 2 Clinical Study Of EB06 In Moderate-To-Severe Nonsegmental Vitiligo

Edesa Biotech shares are trading higher after CEO Pardeep Nijhawan bought 10,000 shares at an average price of $3.63 per share. That purchase brought the CEO's weekly buying to 23,000 shares this week, increasing his stake to about 1.37 million shares.

Edesa Biotech shares are trading higher after CEO Pardeep Nijhawan bought 10,000 shares at an average price of $3.63 per share. That purchase brought the CEO's weekly buying to 23,000 shares this week, increasing his stake to about 1.37 million shares.

On Tuesday, there are stocks with unusual volume. Let's take a look.

EDSA: Strengthened Phase 3 ARDS Data Shows Significant Reduction in 28-Day Mortality

The trading volume of these stocks is deviating from the norm in today's session.

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

Reported Earlier: Edesa Biotech Reports Phase 3 Data Show Paridiprubart Cuts 28-Day Mortality To 24% From 33% Across 278 Patients; Targeting Sepsis, Acute Kidney Injury And Pneumonia With New Patent Filings

Edesa Biotech shares are trading higher after the company announced additional data from a Phase 3 study of paridiprubart.

Edesa Biotech Announces Additional Data From Phase 3 Study Of Paridiprubart

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

Edesa Biotech Q1 EPS $(0.28) Beats $(0.45) Estimate

EDSA: Gearing Up to Initiate Phase 2 Vitiligo Trial in Mid-2026

Edesa Biotech Reports Fiscal Year 2025 Results

Edesa Biotech Q4 EPS $(0.32) Misses $(0.27) Estimate